Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This review considers the therapeutic choices currently faced by people with type 2 diabetes and those caring for them when glucose levels initially controlled with lifestyle management and metformin start to rise. While sulphonylureas are familiar agents and cheaper than other alternatives, they cause hypoglycaemia and modest weight gain, and robust outcome data are still lacking. Dipeptidyl peptidase 4 inhibitors ('gliptins') have an attractive pharmacological and adverse effect profile, but their effects on the cardiovascular system are also uncertain. Thiazolidinediones ('glitazones') are effective glucose-lowering agents, but cause weight gain and increase the risk of fracture, while the cardiovascular benefits hoped for in association with 'insulin-sensitization' have not been as expected. Glucagon-like peptide-1 agonists will not be acceptable as initial second-line agents for many people as they are injectable rather than oral. Well-powered 'head-to-head' clinical trials of adequate duration are therefore required to allow evidence-based decisions on second-line therapy.

Original publication

DOI

10.1093/qjmed/hcq237

Type

Journal article

Journal

QJM : monthly journal of the Association of Physicians

Publication Date

03/2011

Volume

104

Pages

185 - 192

Addresses

BHF Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK. john.petrie@glasgow.ac.uk

Keywords

Humans, Diabetes Mellitus, Type 2, Weight Gain, Metformin, Sulfonylurea Compounds, Thiazolidinediones, Hypoglycemic Agents, Risk Factors, Drug Synergism, Fractures, Bone, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors